First Time Loading...

Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 4.475 USD -5.39% Market Closed
Updated: Apr 18, 2024

Intrinsic Value

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. [ Read More ]

The intrinsic value of one DCTH stock under the Base Case scenario is 17.363 USD. Compared to the current market price of 4.475 USD, Delcath Systems Inc is Undervalued by 74%.

Key Points:
DCTH Intrinsic Value
Base Case
17.363 USD
Undervaluation 74%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Delcath Systems Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DCTH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Delcath Systems Inc

Provide an overview of the primary business activities
of Delcath Systems Inc.

What unique competitive advantages
does Delcath Systems Inc hold over its rivals?

What risks and challenges
does Delcath Systems Inc face in the near future?

Has there been any significant insider trading activity
in Delcath Systems Inc recently?

Summarize the latest earnings call
of Delcath Systems Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Delcath Systems Inc.

Provide P/S
for Delcath Systems Inc.

Provide P/E
for Delcath Systems Inc.

Provide P/OCF
for Delcath Systems Inc.

Provide P/FCFE
for Delcath Systems Inc.

Provide P/B
for Delcath Systems Inc.

Provide EV/S
for Delcath Systems Inc.

Provide EV/GP
for Delcath Systems Inc.

Provide EV/EBITDA
for Delcath Systems Inc.

Provide EV/EBIT
for Delcath Systems Inc.

Provide EV/OCF
for Delcath Systems Inc.

Provide EV/FCFF
for Delcath Systems Inc.

Provide EV/IC
for Delcath Systems Inc.

Show me price targets
for Delcath Systems Inc made by professional analysts.

What are the Revenue projections
for Delcath Systems Inc?

How accurate were the past Revenue estimates
for Delcath Systems Inc?

What are the Net Income projections
for Delcath Systems Inc?

How accurate were the past Net Income estimates
for Delcath Systems Inc?

What are the EPS projections
for Delcath Systems Inc?

How accurate were the past EPS estimates
for Delcath Systems Inc?

What are the EBIT projections
for Delcath Systems Inc?

How accurate were the past EBIT estimates
for Delcath Systems Inc?

Compare the revenue forecasts
for Delcath Systems Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Delcath Systems Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Delcath Systems Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Delcath Systems Inc compared to its peers.

Compare the P/E ratios
of Delcath Systems Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Delcath Systems Inc with its peers.

Analyze the financial leverage
of Delcath Systems Inc compared to its main competitors.

Show all profitability ratios
for Delcath Systems Inc.

Provide ROE
for Delcath Systems Inc.

Provide ROA
for Delcath Systems Inc.

Provide ROIC
for Delcath Systems Inc.

Provide ROCE
for Delcath Systems Inc.

Provide Gross Margin
for Delcath Systems Inc.

Provide Operating Margin
for Delcath Systems Inc.

Provide Net Margin
for Delcath Systems Inc.

Provide FCF Margin
for Delcath Systems Inc.

Show all solvency ratios
for Delcath Systems Inc.

Provide D/E Ratio
for Delcath Systems Inc.

Provide D/A Ratio
for Delcath Systems Inc.

Provide Interest Coverage Ratio
for Delcath Systems Inc.

Provide Altman Z-Score Ratio
for Delcath Systems Inc.

Provide Quick Ratio
for Delcath Systems Inc.

Provide Current Ratio
for Delcath Systems Inc.

Provide Cash Ratio
for Delcath Systems Inc.

What is the historical Revenue growth
over the last 5 years for Delcath Systems Inc?

What is the historical Net Income growth
over the last 5 years for Delcath Systems Inc?

What is the current Free Cash Flow
of Delcath Systems Inc?

Financials

Balance Sheet Decomposition
Delcath Systems Inc

Current Assets 37.2m
Cash & Short-Term Investments 32.5m
Receivables 392k
Other Current Assets 4.3m
Non-Current Assets 1.5m
PP&E 1.5m
Current Liabilities 16.4m
Accounts Payable 1m
Accrued Liabilities 5.3m
Other Current Liabilities 10.2m
Non-Current Liabilities 6.4m
Other Non-Current Liabilities 6.4m
Efficiency

Earnings Waterfall
Delcath Systems Inc

Revenue
2.1m USD
Cost of Revenue
-635k USD
Gross Profit
1.4m USD
Operating Expenses
-39.6m USD
Operating Income
-38.2m USD
Other Expenses
-9.5m USD
Net Income
-47.7m USD

Free Cash Flow Analysis
Delcath Systems Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DCTH Profitability Score
Profitability Due Diligence

Delcath Systems Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
27/100
Profitability
Score

Delcath Systems Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

DCTH Solvency Score
Solvency Due Diligence

Delcath Systems Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
40/100
Solvency
Score

Delcath Systems Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DCTH Price Targets Summary
Delcath Systems Inc

Wall Street analysts forecast DCTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DCTH is 18.768 USD with a low forecast of 13.13 USD and a high forecast of 23.1 USD.

Lowest
Price Target
13.13 USD
193% Upside
Average
Price Target
18.768 USD
319% Upside
Highest
Price Target
23.1 USD
416% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DCTH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DCTH Price
Delcath Systems Inc

1M 1M
+7%
6M 6M
+18%
1Y 1Y
-21%
3Y 3Y
-63%
5Y 5Y
-96%
10Y 10Y
-100%
Annual Price Range
4.475
52w Low
2.25
52w High
7.96
Price Metrics
Average Annual Return -51.31%
Standard Deviation of Annual Returns 26.81%
Max Drawdown -98%
Shares Statistics
Market Capitalization 120.3m USD
Shares Outstanding 25 439 300
Percentage of Shares Shorted 3.87%

DCTH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Delcath Systems Inc Logo
Delcath Systems Inc

Country

United States of America

Industry

Health Care

Market Cap

120.3m USD

Dividend Yield

0%

Description

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

Contact

NEW YORK
New York City
1633 Broadway Ste 22C
+12124892100.0
http://delcath.com/

IPO

2000-10-19

Employees

45

Officers

CEO & Director
Mr. Gerard J. Michel MBA, MS
Senior Vice President Clinical Development & Medical Affairs
Dr. Johnny John M.D.
Senior VP of Finance and Principal Financial & Accounting Officer
Ms. Sandra Pennell
Chief Operating Officer
Dr. Martha S. Rook Ph.D.
General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. David Hoffman
Chief Medical Officer
Dr. Vojislav Vukovic M.D., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one DCTH stock?

The intrinsic value of one DCTH stock under the Base Case scenario is 17.363 USD.

Is DCTH stock undervalued or overvalued?

Compared to the current market price of 4.475 USD, Delcath Systems Inc is Undervalued by 74%.